Controversies in preconception, preimplantation and prenatal genetic diagnosis: How will genetics technology drive the future?

Data: 25/27-9-2015
Luogo: Parigi (Francia), Novotel Tour Eiffel Hotel
Chairman: Simon Fishel


Saturday, September 26, 2015
  Session 1 Introduction to Genetics
  Welcome Simon Fishel, UK
  Basic principles for the non-geneticist Brigitte Faas, The Netherlands
  Next generation sequencing: strategies for genetic testing Mark Hughes, USA
  Technical aspects of reproductive genetics (Methods of PGS, PGD, Prenatal) Darren Griffin, UK
  Carrier screening of recessive disease: Universal screening Gabriel Lazarin, USA
  Session 2 PGD and PGS: State-of-the-Art
  Development and current best practice for translocations Svetlana Rechitsky, USA
  Single gene diagnosis and aneuploidy detection using karyomapping Tony Gordon, UK
  Clinically evaluating NGS and its extra information Dagan Wells, UK
  PGS for advanced maternal age Ariel Hourvitz, Israel
  Session 3 The clinical value of Preimplantation Genetic Screening (PGS)
  Management of PGS treatment embryo: timing, technology, success and cost effectiveness Richard Scott, USA
  Aneuploidy in embryos: variability between centers, between patients and between cycles of the same patients Santiago Munné, USA
  Debate: Is it now unethical not to screen out an aneuploidy embryo in IVF? For: Andreas Schmutzler, Germany Against: Sjoerd Repping, The Netherlands
  Session 4 Prediction of Gamete quality and viability
  Cumulus cell genomics and its predictive value Samir Hamamah, France
  Blastocoel analysis for PGS and the potential clinical value of mitochondrial screening assays Luca Gianaroli, Italy
  Ultra-sensitive mass spectrometry to look at the proteomic content of the blastocoel fluid with a view to embryo viability assessment Maurizio Poli, UK
  Update on polar body testing for detection of female meiotic errors Alan Handyside, UK


Sunday, September 27, 2015
  Session 5 Non-Invasive Prenatal Testing (NIPT): Current state of the ART
  Introduction of NIPT in clinical practice Dick Oepkes, The Netherlands
  Debate : How should NIPT be used Moderator: Dick Oepkes, The Netherlands - As primary screening to all patients Tom Musci, USA- As contingent screening in very high and intermediate risk patients Howard Cuckle, USA/Israel
  Session 6 Non-Invasive Prenatal Testing (NIPT): Future Perspectives
  Debate: NIPT for microdeletion syndromes Pros: Amy Sehnert, USA Cons: Tom Musci, USA
  NIPT for Single-Gene Disorders Lyn Chitty, UK
  Future development in NIPT Rossa W.K. Chiu, Hong Kong
Session 7 Chromosomal microarrays (CMA) in Prenatal Diagnosis
  Chromosomal microarrays - how does it work? Vincenzo Cirigliano, Spain
  Can CMA replace standard karyotyping? Francesco Fiorentino, Italy
  Counseling for Variants of Unclear Clinical Significance Brigitte Faas, The Netherlands
  Debate: Would it be ethical not to propose women to undergo invasive testing with CMA? Moderator: TBD For: TBD Against: Yuval Yaron, Israel
  Session 8 Genetics in infertility
  Characterization of the molecular etiology of severe cases of infertility - a must to bring personalized medicine to the field of reproduction Pierre Ray, France
  Carrier screening of genes relevant in infertility, including mutations associated with miscarriage Alex Bisignano, USA
  Gene therapy in reproductive medicine Gregory Christman, USA
  Social and legal aspects Francoise Shenfield, UK

Contact Comtec Med

TEVAGYN è una testata rivolta ai ginecologi di TEVA Italia Srl – Viale del Mulino 1 – Edificio U10 – Assago P.I. 11654150157 Powered by NT2 - Nuove Tecnologie